510(k) device
EksoNR
Ekso Bionics, Inc. · Powered Exoskeleton (PHL, Class II) · First FDA decision Jun 19, 2020, newest Jun 9, 2022Mobility impairmentSpinal cord injury and paralysis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
10
Naming "EksoNR"
MAUDE reports
1
Brand "EksoNR", since 2015
PubMed studies
3
Mentioning "EksoNR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EksoNR
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- EksoNR510(k)
K220988 · Decided Jun 9, 2022 · 66 days after receipt
Device type: Powered Exoskeleton (PHL) · Physical Medicine & Rehabilitation
- EksoNR510(k)
K200574 · Decided Jun 19, 2020 · 106 days after receipt
Device type: Powered Exoskeleton (PHL) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EksoNR", any status and sponsor, newest update first.
The State Academy of Applied Sciences in KoszalinAcademic, hospital or other
NCT07499063 · 25 participants · Start May 10, 2026 · Primary completion Jun 1, 2026
Device: Ekso NR Exoskeleton · For: Gait Analysis in Healthy Subjects
Sites: Koszalin, Poland
- Early Robotic Gait Training After StrokeRecruiting
Baylor Research InstituteAcademic, hospital or other
NCT06430632 · 54 participants (planned) · Start Mar 1, 2024 · Primary completion Dec 2026
Device: Robotic Gait Training · For: Stroke
Sites: Dallas, Texas
Somogy Megyei Kaposi Mór Teaching HospitalAcademic, hospital or other
NCT07352085 · 5 participants · Start Jun 1, 2024 · Primary completion Feb 28, 2025
Device: Gait training with exoskeleton · For: Stroke; Spinal Cord Injuries (Complete and Incomplete); Cerebellar Ataxia and 1 more
Sites: Kaposvár, Hungary
7 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EksoNR", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PHL
57 reports: 7 malfunction, 50 injury, 0 death
Newest reports for this brand
- EKSONRInjury
3009495988-2023-00001 · Received May 10, 2023 · Event dated Apr 14, 2023
Device type: Powered Exoskeleton (PHL)
Device problem as coded: Use of Incorrect Control/Treatment Settings
Patient problem as coded: Sepsis; Limb Fracture
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "EksoNR"[tiab]. The summary above synthesizes these.
- Influence of gait-synchronized functional electrical stimulation during exoskeleton-assisted ambulation on cardiorespiratory outcomes in individuals with incomplete spinal cord injury.
Voicu R, Kuchen DB, Perret C, et al. · J Rehabil Med · 2025Randomized Controlled Trial
- Enhanced Rehabilitation Outcomes of Robotic-Assisted Gait Training with EksoNR Lower Extremity Exoskeleton in 19 Stroke Patients.
Wiśniowska-Szurlej A, Wooszyn N, Brożonowicz J, et al. · Med Sci Monit · 2023Observational Study
- Gait rehabilitation outcomes with EksoNR: an exploratory study comparing progressive vs. non-progressive neurological impairments.
Vijayvargiya A, Langan R, Byrne D, et al. · Disabil Rehabil · 2026Comparative Study
Other devices of this type
Also filed under product code PHL.
- Indego(R)Parker-Hannifin Corporation · 510(k) 2018
- Atalante XWandercraft SAS · 510(k) 2025
- ReWalk P6.0Re Walk Robotics , Ltd. · 510(k) 2023
- HAL for Medical Use(Lower Limb type)Cyberdyne, Inc. · 510(k) 2020
- Ekso (version 1.1) and Ekso GT (version 1.2)Ekso Bionics, Inc. · 510(k) 2016
- Trexo TheoTrexo Robotics, Inc. · 510(k) 2026
- EveWandercraft SAS · 510(k) 2026
- ReWalk® 7 Personal Exoskeleton (50-20-0005)Rewalk Robotics Ltd. Dba Lifeward · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.